Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Nov;92(5):2540–2545. doi: 10.1172/JCI116863

Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.

A H Schmaier 1, L D Dahl 1, A J Rozemuller 1, R A Roos 1, S L Wagner 1, R Chung 1, W E Van Nostrand 1
PMCID: PMC288440  PMID: 8227367

Abstract

Protease nexin-2/amyloid beta protein precursor (PN-2/A beta PP) is an abundant, secreted platelet protein which is a potent inhibitor of coagulation Factor XIa. We examined other potential anticoagulant activities of PN-2/A beta PP. Purified Kunitz protease inhibitor domain of PN-2/A beta PP and PN-2/A beta PP itself were found to prolong the coagulation time of plasma and pure Factor IXa. The Kunitz protease inhibitor domain also inhibited the ability of Factor IXa to activate Factor X. PN-2/A beta PP inhibited Factor IXa with a Ki of 7.9 to 3.9 x 10(-11) M in the absence and presence of heparin, respectively. When the second-order rate constant of PN-2/A beta PP's inhibition of Factor IXa (2.7 x 10(8) M-1min-1) was compared to that of antithrombin III (3.8 x 10(6) M-1min-1), PN-2/A beta PP was at least a 71-fold more potent inhibitor of Factor IXa than antithrombin III. PN-2/A beta PP formed a complex with Factor IXa as detected by gel filtration and ELISA. The finding that PN-2/A beta PP is a potent inhibitor of Factor IXa could help to explain the spontaneous intracerebral hemorrhages seen in patients with hereditary cerebral hemorrhage with amyloidosis Dutch-type where there is an extensive accumulation of PN-2/A beta PP in their cerebral blood vessels.

Full text

PDF
2540

Images in this article

2544Image
on p.2544

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S. S., Rawala-Sheikh R., Walsh P. N. Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem. 1989 Feb 25;264(6):3244–3251. [PubMed] [Google Scholar]
  2. Bieth J. G. In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med. 1984 Dec;32(3):387–397. doi: 10.1016/0006-2944(84)90046-2. [DOI] [PubMed] [Google Scholar]
  3. Biggs R. Haemophilia treatment in the United Kingdom from 1969 to 1974. Br J Haematol. 1977 Apr;35(4):487–504. doi: 10.1111/j.1365-2141.1977.tb00615.x. [DOI] [PubMed] [Google Scholar]
  4. Bolton-Maggs P. H., Young Wan-Yin B., McCraw A. H., Slack J., Kernoff P. B. Inheritance and bleeding in factor XI deficiency. Br J Haematol. 1988 Aug;69(4):521–528. doi: 10.1111/j.1365-2141.1988.tb02409.x. [DOI] [PubMed] [Google Scholar]
  5. Gigli I., Mason J. W., Colman R. W., Austen K. F. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol. 1970 Mar;104(3):574–581. [PubMed] [Google Scholar]
  6. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]
  7. Griffith M. J., Breitkreutz L., Trapp H., Briet E., Noyes C. M., Lundblad R. L., Roberts H. R. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill. J Clin Invest. 1985 Jan;75(1):4–10. doi: 10.1172/JCI111694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 Feb 19;325(6106):733–736. doi: 10.1038/325733a0. [DOI] [PubMed] [Google Scholar]
  9. Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., van Duinen S. G., Bots G. T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990 Jun 1;248(4959):1124–1126. doi: 10.1126/science.2111584. [DOI] [PubMed] [Google Scholar]
  10. Lundblad R. L., Roberts H. R. The acceleration by polylysine of the activation of factor X by factor IXa. Thromb Res. 1982 Feb 15;25(4):319–329. doi: 10.1016/0049-3848(82)90232-8. [DOI] [PubMed] [Google Scholar]
  11. Luyendijk W., Bots G. T., Vegter-van der Vlis M., Went L. N., Frangione B. Hereditary cerebral haemorrhage caused by cortical amyloid angiopathy. J Neurol Sci. 1988 Jul;85(3):267–280. doi: 10.1016/0022-510x(88)90186-4. [DOI] [PubMed] [Google Scholar]
  12. McCord D. M., Monroe D. M., Smith K. J., Roberts H. R. Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. J Biol Chem. 1990 Jun 25;265(18):10250–10254. [PubMed] [Google Scholar]
  13. Oltersdorf T., Fritz L. C., Schenk D. B., Lieberburg I., Johnson-Wood K. L., Beattie E. C., Ward P. J., Blacher R. W., Dovey H. F., Sinha S. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature. 1989 Sep 14;341(6238):144–147. doi: 10.1038/341144a0. [DOI] [PubMed] [Google Scholar]
  14. Ponte P., Gonzalez-DeWhitt P., Schilling J., Miller J., Hsu D., Greenberg B., Davis K., Wallace W., Lieberburg I., Fuller F. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature. 1988 Feb 11;331(6156):525–527. doi: 10.1038/331525a0. [DOI] [PubMed] [Google Scholar]
  15. RAPAPORT S. I., PROCTOR R. R., PATCH M. J., YETTRA M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood. 1961 Aug;18:149–165. [PubMed] [Google Scholar]
  16. Rosenberg J. S., McKenna P. W., Rosenberg R. D. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975 Dec 10;250(23):8883–8888. [PubMed] [Google Scholar]
  17. Rozemuller A. J., Roos R. A., Bots G. T., Kamphorst W., Eikelenboom P., Van Nostrand W. E. Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease. Am J Pathol. 1993 May;142(5):1449–1457. [PMC free article] [PubMed] [Google Scholar]
  18. Scott C. F., Schapira M., James H. L., Cohen A. B., Colman R. W. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest. 1982 Apr;69(4):844–852. doi: 10.1172/JCI110524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood. 1978 Jun;51(6):1223–1228. [PubMed] [Google Scholar]
  20. Smith R. P., Higuchi D. A., Broze G. J., Jr Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science. 1990 Jun 1;248(4959):1126–1128. doi: 10.1126/science.2111585. [DOI] [PubMed] [Google Scholar]
  21. Stern D. M., Drillings M., Kisiel W., Nawroth P., Nossel H. L., LaGamma K. S. Activation of factor IX bound to cultured bovine aortic endothelial cells. Proc Natl Acad Sci U S A. 1984 Feb;81(3):913–917. doi: 10.1073/pnas.81.3.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Van Broeckhoven C., Haan J., Bakker E., Hardy J. A., Van Hul W., Wehnert A., Vegter-Van der Vlis M., Roos R. A. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science. 1990 Jun 1;248(4959):1120–1122. doi: 10.1126/science.1971458. [DOI] [PubMed] [Google Scholar]
  23. Van Nostrand W. E., Schmaier A. H., Farrow J. S., Cines D. B., Cunningham D. D. Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein. Biochem Biophys Res Commun. 1991 Feb 28;175(1):15–21. doi: 10.1016/s0006-291x(05)81193-3. [DOI] [PubMed] [Google Scholar]
  24. Van Nostrand W. E., Wagner S. L., Farrow J. S., Cunningham D. D. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. J Biol Chem. 1990 Jun 15;265(17):9591–9594. [PubMed] [Google Scholar]
  25. Van Nostrand W. E., Wagner S. L., Suzuki M., Choi B. H., Farrow J. S., Geddes J. W., Cotman C. W., Cunningham D. D. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature. 1989 Oct 12;341(6242):546–549. doi: 10.1038/341546a0. [DOI] [PubMed] [Google Scholar]
  26. Wagner S. L., Siegel R. S., Vedvick T. S., Raschke W. C., Van Nostrand W. E. High level expression, purification, and characterization of the Kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor. Biochem Biophys Res Commun. 1992 Jul 31;186(2):1138–1145. doi: 10.1016/0006-291x(92)90865-i. [DOI] [PubMed] [Google Scholar]
  27. van Duinen S. G., Castaño E. M., Prelli F., Bots G. T., Luyendijk W., Frangione B. Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5991–5994. doi: 10.1073/pnas.84.16.5991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES